Virginie Martiny
Research Subjects
Virginie Martiny has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Alex N. Bullock
Centre for Medicines Discovery, Nuffield Department of Medicine University of Oxford Oxford OX3 7FZ UK
2 shared publications - András Kotschy
Servier Research Institute of Medicinal Chemistry Budapest Hungary
2 shared publications Alexandra Bristiel
Institute de Recherche Servier, 22 Route 128, 91190 Gif-sur-Yvette, France
1 shared publicationAndras Herner
Servier Research Institute of Medicinal Chemistry, Záhony u. 7., H-1031 Budapest, Hungary
1 shared publication- Andras Herner
Servier Research Institute of Medicinal Chemistry Budapest Hungary
1 shared publication Arpad Kiss
Servier Research Institute of Medicinal Chemistry Budapest Hungary
1 shared publication
Latest Publications
- Open Access
- 25 August 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (16)
Structure‐Guided Optimization of a Molecular Glue Targeting the KBTBD4‐HDAC1/2 Complex
Optimization of UM171, a molecular glue initiating the degradation of neosubstrate HDAC1/2–CoREST–LSD1 through a multiprotein complex formed with KBTBD4, was carried out using the cryo‐EM structure of its KBTBD4‐HDAC2 complex. Structural modifications resulted in a 20‐fold improvement in glue activity, demonstrated by the stability of its ternary complex with KBTBD4‐HDAC2. These improvements were also accompanied by a robust degradation of LSD1 and the CoREST1 protein. Our results, although promising, also highlight the complexity of structure‐guided glue design. The effect of the developed glues on the viability of HepG2 cells revealed a varying level of toxicity, which was disconnected from the glue activity. These observations highlight the potential impact of off‐target effects on the biological activity of these glues.
- 25 August 2026
- Published by Wiley in ChemMedChem
- Vol. 21 (16)
Open AccessStructure‐Guided Optimization of a Molecular Glue Targeting the KBTBD4‐HDAC1/2 Complex
Optimization of UM171, a molecular glue initiating the degradation of neosubstrate HDAC1/2–CoREST–LSD1 through a multiprotein complex formed with KBTBD4, was carried out using the cryo‐EM structure of its KBTBD4‐HDAC2 complex. Structural modifications resulted in a 20‐fold improvement in glue activity, demonstrated by the stability of its ternary complex with KBTBD4‐HDAC2. These improvements were also accompanied by a robust degradation of LSD1 and the CoREST1 protein. Our results, although promising, also highlight the complexity of structure‐guided glue design. The effect of the developed glues on the viability of HepG2 cells revealed a varying level of toxicity, which was disconnected from the glue activity. These observations highlight the potential impact of off‐target effects on the biological activity of these glues.
- Open Access
- 21 November 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (23) , 21208-21222
Covalent Inhibitors of KEAP1 with Exquisite Selectivity
The NRF2-KEAP1 interaction is central for cytoprotection against stresses, giving it high clinical significance. Covalent modification of KEAP1 is an efficient approach, but the covalent inhibitors used in the clinic carry undesired side effects originating in their moderate selectivity. Starting with a phenotypic screen, we identified a new covalent inhibitor chemotype that was optimized to deliver a series of potent and highly selective KEAP1 binders. While the developed compounds showed both cellular and in vivo activity, upregulating antioxidant response element-dependent target genes, they showed no genotoxicity in vitro. The lead compound exhibited broad selectivity in activity-based protein profiling and showed no significant interaction with a panel of commonly studied receptors nor with a broad panel of kinases. The nature of its interaction with KEAP1 and the origin of its selectivity were revealed by X-ray crystallography.
- 21 November 2024
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (23) , 21208-21222
Open AccessCovalent Inhibitors of KEAP1 with Exquisite Selectivity
The NRF2-KEAP1 interaction is central for cytoprotection against stresses, giving it high clinical significance. Covalent modification of KEAP1 is an efficient approach, but the covalent inhibitors used in the clinic carry undesired side effects originating in their moderate selectivity. Starting with a phenotypic screen, we identified a new covalent inhibitor chemotype that was optimized to deliver a series of potent and highly selective KEAP1 binders. While the developed compounds showed both cellular and in vivo activity, upregulating antioxidant response element-dependent target genes, they showed no genotoxicity in vitro. The lead compound exhibited broad selectivity in activity-based protein profiling and showed no significant interaction with a panel of commonly studied receptors nor with a broad panel of kinases. The nature of its interaction with KEAP1 and the origin of its selectivity were revealed by X-ray crystallography.
- Open Access
- 22 August 2022
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 36 (9) , 639-651
FastGrow: on-the-fly growing and its application to DYRK1A
Fragment-based drug design is an established routine approach in both experimental and computational spheres. Growing fragment hits into viable ligands has increasingly shifted into the spotlight. FastGrow is an application based on a shape search algorithm that addresses this challenge at high speeds of a few milliseconds per fragment. It further features a pharmacophoric interaction description, ensemble flexibility, as well as geometry optimization to become a fully fledged structure-based modeling tool. All features were evaluated in detail on a previously reported collection of fragment growing scenarios extracted from crystallographic data. FastGrow was also shown to perform competitively versus established docking software. A case study on the DYRK1A kinase, using recently reported new chemotypes, illustrates FastGrow’s features in practice and its ability to identify active fragments. FastGrow is freely available to the public as a web server at https://fastgrow.plus/ and is part of the SeeSAR 3D software package.
- 22 August 2022
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 36 (9) , 639-651
Open AccessFastGrow: on-the-fly growing and its application to DYRK1A
Fragment-based drug design is an established routine approach in both experimental and computational spheres. Growing fragment hits into viable ligands has increasingly shifted into the spotlight. FastGrow is an application based on a shape search algorithm that addresses this challenge at high speeds of a few milliseconds per fragment. It further features a pharmacophoric interaction description, ensemble flexibility, as well as geometry optimization to become a fully fledged structure-based modeling tool. All features were evaluated in detail on a previously reported collection of fragment growing scenarios extracted from crystallographic data. FastGrow was also shown to perform competitively versus established docking software. A case study on the DYRK1A kinase, using recently reported new chemotypes, illustrates FastGrow’s features in practice and its ability to identify active fragments. FastGrow is freely available to the public as a web server at https://fastgrow.plus/ and is part of the SeeSAR 3D software package.